Compare Macy's Inc (M) vs Summit Therapeutics Inc (SMMT) Price & Performance

Macy's (M) trades at $22.79 with strong valuation metrics including a P/E of 8.35 and P/S of 0.27, suggesting potential undervaluation. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.63 exceeding expectations by 70%. Technical indicators show a bullish trend with support at $22 and resistance at $23-24, while the RSI at 28.95 suggests potential oversold conditions. Recent news highlights Macy's 'Bold New Chapter' strategy driving digital transformation and sales growth.

The outlook remains cautiously optimistic with a 3.5% dividend yield providing income support. Analyst consensus targets $24.25 with 32% buy ratings, though execution risks persist amid retail sector challenges. Key catalysts include continued digital transformation success and margin improvement, while risks involve competitive pressures and uneven quarterly performance.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.